Orlando, FL -- (SBWIRE) -- 10/29/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), VIVUS, Inc. (NASDAQ:VVUS).
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares declined 1.87% to $23.62. Equities research analysts at Ned Davis Research started coverage on shares of ACADIA in a research note issued to investors on Oct. 8. The firm set a “neutral” rating on the stock.
Additionally, ACAD’s CMO Roger Mills sold 35,965 shares of ACADIA Pharmaceuticals stock on the open market in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $25.01, for a total value of $899,484.65.
Are investors worried about the recent updates with ACAD? Find out with a free trend analysis HERE
VIVUS, Inc. (NASDAQ:VVUS) shares jumped 2.13% to $9.59. The company on Oct. 11 announced the signing of an agreement providing Auxilium Pharmaceuticals, Inc. (Nasdaq:AUXL) the exclusive rights to market STENDRA™ (avanafil) in the United States and Canada. The parties also simultaneously signed a Commercial Supply Agreement pursuant to which VIVUS will be responsible for the manufacture and supply of STENDRA to Auxilium for a mutually agreed term.
Additionally, the company on Oct. 9 announced new data published online in Diabetes Care demonstrating the effects of Qsymia (phentermine and topiramate extended-release) capsules CIV, on the progression to type 2 diabetes.
Is VVUS going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)